UA138404U - METHOD FOR PREDICTING THE DEVELOPMENT OF OSTEOARTHRITIS - Google Patents

Abstract

The method of predicting the development of osteoarthritis includes clinical examination, radiography, according to the utility model in addition to the serum of the patient determine the gene polymorphism of methylenetetrahydrofolate reductase (MTHFR C677T), nitric oxide synthase (eNOS T786C), 6 ) and with a homozygous carrier of 677-TT, 786-CC and endothelin levels> 10 ng / ml, GAG> 28 μmol / l, IL-6> 10 ng / l predict the development of osteoarthritis.

Description

A useful model belongs to medicine, in particular to orthopedics and rheumatology. It is prescribed and can be used in diagnosing the development of osteoarthritis in the early stages.

Methods of predicting the development of osteoarthritis are known. These include x-rays, examination of biopsies of the synovial membrane, synovial fluid, and cartilage biopsies (A.N.

Okorokov Diagnosis of diseases of internal organs. M., 2001. - vol. 2. - pp. 186-196). The disadvantage of these methods is the lack of the possibility of predicting the dynamics of the process in the early subclinical stages, preventing its development and possible complications due to the internal characteristics of the body.

The basis of a useful model is the task of developing a method that would allow predicting the development of osteoarthritis in the early stages.

The task is solved by the fact that, in addition to clinical examination and radiography, polymorphism of methylenetetrahydrofolate reductase genes (MTNEK) is determined in the patient's blood serum

Сб677Т), nitric oxide synthase (emo5 1Т786С), content of endothelin, glycosaminoglycans (GAG), interleukin 6 (IL-6). With homozygous carrier 677-TT, 786-SS, endothelin levels 210 ng/ml,

GAG »28 μmol/l, IL-6 »10 ng/l predict the development of osteoarthritis.

Application of the method. Upon admission, the patient is examined, an X-ray is taken, the polymorphism of MTNEK C677tT, eMmo5 T786C genes is determined, the content of endothelin, HAG, IL-6 is determined by the immunoenzymatic method. With homozygous carrier 677-TT, 786-SS, endothelin levels 210 ng/ml,

GAG »28 μmol/l, IL-6 210 ng/l predict the development of osteoarthritis.

A specific example of using the method.

Patient 3., 59 years old, was admitted to the clinic due to pain syndrome in the right knee joint. Examined, X-ray taken. No signs of osteoarthritis were found. The polymorphism of MTNEK C677tT and emoz T786C genes was determined in blood serum. The content of endothelin, GAG, and IL-6 was determined by immunoenzymatic method. Homozygous carriers of 677-TT and 786-SS were established, endothelin levels - 20 ng/ml, GAG - 48 μmol/l, IL-6-22 ng/l. The development of osteoarthritis was diagnosed. After 12 months, X-rays revealed signs of osteoarthritis.

Thus, the proposed method is informative and allows diagnosing the development of osteoarthritis at an early stage.

Coo)

Claims (1)

USEFUL MODEL FORMULA The method of predicting the development of osteoarthritis, which includes a clinical examination, radiography, which is distinguished by the fact that in the patient's blood serum polymorphisms of the genes methylenetetrahydrofolate reductase (MTNEK C677T), nitric oxide synthase (EeMO5 T786S), the content of endothelin, glycosaminoglycans (GAG), interleukin 6 (IL-6) and, in case of homozygous carrier 6 77- 17, 786-SS and endothelin levels of 210 ng/ml, GAG »28 μmol/l, IL-b6 »10 ng/l predict the development of osteoarthritis.